Member Info for hasiba

Hi everyone..
I bought today just over 101000 at 16.27 hrs but it is showing as sell trade!
Obviously many of these trades around my time are buys and not sells trade as showing here!
I have been watching this when it peaked to 16 p and looked at in more details..I put some money here as it appears to have good potentials from here..GLA

https://uk.investing.com/news/commodities-news/oil-prices-jump-2-after-iranian-oil-tanker-explosion-raises-supply-concerns-1977638

Last call for boarding!

Just wondering!
:)

ust turned blue..
1,582,199 one Share trade bought...encouraging

https://www.gov.uk/government/news/development-of-new-antibiotics-encouraged-with-new-pharmaceutical-payment-system

Morning all
RNS just confirming what was suggested to the fda in their last meeting. More details required by motif to tell investors of the fda minutes..and their actions or discussions with other partners if any in the last few months..estimate of costs..etc
Finding a partner or a buyer to spend and finance the trial is the issue but at least no resignation and all bod in place ,new nomads brokerages.
Let’s hope for better news..for every investors sake..
Holding and hoping..
No need to keep bashing motif more than where it is now.....guys give it a rest.
Sp may turn blue later..here is hoping for one happier day!

Bailedintime...
All trials agreed through fda must be controlled with certain objectives and effectiveness.
Single trial does not mean necessarily a comparison trial with other Antibiotics or placebo.

See the last paragraph of this copied of trial research studies:
‘ Single-arm or non-randomized trials, in which everyone enrolled in a trial receives the experimental therapy, are common in Phase 1 and 2 testing. While Phase 3 trials are frequently randomized in order to provide more precise data on safety and effectiveness outcomes, a Phase 3 trial might use a single arm if a small target population makes conducting a randomized trial impractical. In these cases, researchers must use endpoints like response rate that can demonstrate clinical impact in the absence of direct comparison data. “

Do you mean a single trial proposed by motif must be a comparable one as the one they did in phase3??
I don’t think so myself otherwise what’s the point of motif proposal to the fda !
The fda asked for more data and the unusual situation motif is left with is for them to sugges a simple single trial to confirm or refute of dili. This makes more sense than to conduct another expensive double trial which will take a long time years probably and far more expensive to conduct. The fda concerns mainly about Iclaprim potential dili..
We will have to wait for the fda minutes and actual requirements...

You welcome ..RN

RosieNas..
As in my last post..motif is right to suggest single trial rather than double trial as there is no need to compare with another antibiotic because the fda raised their concerns about potential dili only with Iclaprim. Single trial is cost effective and far less complicated and faster to achieve its purpose..
That how I understand their rns statement which is very sensible .Motif should not need to have another antibiotic such as Vancomycin to compare for efficacy as this is not the issue concerning the fda . Iclaprim potential dili and efficacy in a single trial can be assessed at a much cheaper costs.
Single trial is commonly used in new vaccine to its efficacy and side effects against certain virus or viruses..
Let’s see what the fda reply! Which is the most important.
GL

Cost 50 m phase 3 trial!!
Not so as the average is $19 m if it was comparison trial with another antibiotic but motif is suggesting to the fda a much cheaper trial of a mono therapy trial without comparison . Motif suggestions make sense if the fda concerns of potential liver toxicity only but not efficacy as this has already been confirmed in their comparison trial with Vancomycin.
Mono-therapy trial is much cheaper if agreed by the fda..
Let’s wait the fda minutes..
Dyor please

Yes Latino..your are correct and many hoped this too for a phase4 post marketing trial post approval but the fda chose the other safest route to avoid bad publicity if Iclaprim to cause liver toxicity and death.. they kicked motif badly .
I really hope one day Iclaprim gets approval as its needs is there in many Other conditions too and to save lives....
Iclaprim is superior and good alternative to Vancomycin as the latter is nephrotoxic and Iclaprim is not in addition to increasing bacteria resistance to Vancomycin.
Iclaprim is an analogue to the commonly used Oral antibiotic Trimethoprim which has been used safely for decades...and effectively in many conditions.

Sheltie...
Your last post is objective and this is why I decided then to buy at around 3 p and leveraging down! As I believed the ceo over optimistic voice and explanations then and declined to listen to others advice...and now I feel misled by the muppets at the helm headed by incompetent ceo...
Still there maybe very small hope and some newbies here and veterans support this hopeful view..
Let’s wait to see what happens..
It is not over yet till the fat lady sings...
I am reading all objective posts here and some are encouraging!
Still holding

Thaiflyer1..
If the trial results did not show the bilirubin rise ..they could have approved it.
The bilirubin rise was crucial marker and slightly more patients showed liver enzymes rise in a small trial of 600 gave doubt to fda before approval. That is why the fda did not reject it outright but encouraged motif to carry on with another trial before approval.

Cont....corrections..IT SHOULD READ:
600 patient trial was not enough in fda view to be certain of this.
Hopefully the FDA accept as suggested in the last meeting by motif that these data can be collected WITHOUT another antibiotic comparison as this will be far more expensive than a mono trial..”

Morning all
The issue of FDA asking motif for more data(another trial) can be understood if you read fully the FDA drugs approval process and how they assess the potential liver toxicity and the markers that indicate the cases which led to liver damage and death in a few cases.
In summary Iclaprim did not show evidence of liver toxicity but raised liver enzymes and in the 600 patients trial the no. Of patients who show raised liver enzymes were slightly higher than Vancomycin but one of those patient showed raised bilirubin and all returned to normal level after stopping Iclaprim.
In other drugs that showed liver toxicity and damage ,it was the bilirubin rise that did not go back to normal and liver damage and toxicity occured...
I think the FDA wanted bigger no. Of patients to be sure if bilirubin rise (which is far more crucial) with other liver enzymes would go back to normal if Iclaprim stopped . This obviously must happen before approval.
600 patient trial was not enough in fda view to be certain of this.
Hopefully the FDA accept as suggested in the last meeting by motif that these data can be collected with another antibiotic comparison as this will be far more expensive than a mono trial..

I agree with others the muppets at the helm had misled the investors and were well over optimistic of fda approval.

Still tiny hope...some good objective posts here..
GLA

I look at investing in G as a solid company with safe fundamentals ,growing piles of cash ,future investment growth and expanding and underpinned by big dividends ....
I did not invest here for sp to grow rapidly so I could sell and have short term gains. I do not think you should be buying G for this purpose only...you better find another share like aim share To gamble with this notion.
Sp fluctuations with G...is an emotional thing you should ignore for now with op and no rns coming through to give the market impetus to move the sp in one direction or another..
Enjoy the massive dividends for now and sp rises later...we don’t need to be negative all the time about it..
Holding strong and taking my dividends happily..I am in no rush for the sp to rise now and see it as oppurtunity to add more.
G is a great share to own imo.

Yes Dodger....he stabbed the kurds in the back as he failed recently to support SA against Iran..
The guy is unique character!! Chaos chief creator

Worrying for neighbouring countries with the possibility of isil returns!
More chaos by Trumpy wisdoms !!

I see the SP closing above 200p on consecutive two or three days is a good sign for upwards movement...
All bad news are behind us and positive rumours and speculation to continue.
We are safer now more than any of the recent sp upheaval events.
Shorters are basically gamblers ..they are struggling now to bring the sp below 200 p but are failing
Let’s hope this current trends of moving up continue.
Keep positive..nothing wrong has happened in the last two weeks and sp recovered from 150 p to 206p...fact..
Patience is required..